Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
2.9%
Period ended Dec 31, 2025
Change on a year earlier
+10.1 pts
-7.2% in Q4 2024
History
40 quarters
Since Q4 2015
Sources
40
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 2.9% | +10.1 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | -1.5% | -6.0 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 5.5% | +24.5 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -4.4% | -10.6 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | -7.2% | +5.4 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 4.5% | +20.4 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -19.0% | -22.4 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 6.2% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -12.6% | +41.6 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -15.9% | +44.2 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 3.4% | +27.1 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | -54.2% | -24.2 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -60.1% | -33.9 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -23.7% | +11.1 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | -1.8% | -170.5 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | -30.0% | -457.0 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | -26.2% | -562.3 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | -34.8% | -311.5 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 168.7% | +107.0 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 427.0% | +431.1 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 536.1% | +542.7 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 276.7% | +277.6 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 61.7% | +57.5 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | -4.1% | -5.9 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | -6.6% | -8.9 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -0.9% | +6.4 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | 4.2% | +18.0 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 1.8% | +16.3 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 2.3% | +16.1 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | -7.3% | +11.3 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | -13.8% | -9.7 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | -14.5% | -8.9 pts | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | -13.8% | -4.2 pts | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | -18.6% | -19.7 pts | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | -4.1% | -2.0 pts | SEC Filing (0001104659-17-024344) ↗ |
| Q4 2016 | Dec 31, 2016 | -5.6% | +1.5 pts | SEC Filing (0001104659-17-003920) ↗ |
| Q3 2016 | Sep 30, 2016 | -9.6% | – | SEC Filing (0001104659-16-150813) ↗ |
| Q2 2016 | Jun 30, 2016 | 1.1% | – | SEC Filing (0001104659-16-133433) ↗ |
| Q1 2016 | Mar 31, 2016 | -2.1% | – | SEC Filing (0001104659-16-112689) ↗ |
| Q4 2015 | Dec 31, 2015 | -7.1% | – | SEC Filing (0001104659-16-091861) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) U.S. — Organic / Comparable Sales Growth (%) (%), quarterly Q4 2015–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-yoy-org-us
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.